skip to Main Content
Successful Multi-million Financing Round For SmartDyeLivery GmbH

Successful multi-million financing round for SmartDyeLivery GmbH

  • 2020

Cur­rent financ­ing round with a con­sor­tium of exist­ing and new investors com­pleted, bm‑t beteili­gungs­man­age­ment thürin­gen gmbh increases lead Invest­ment

Smart­Dye­Liv­ery GmbH has suc­cess­fully com­pleted its most recent financ­ing round in the mid-sin­gle-digit mil­lion range. In addi­tion to bm‑t beteili­gungs­man­age­ment thürin­gen gmbh (bm|t), which increased its lead invest­ment, the Stiftung für Tech­nolo­gie, Inno­va­tion und Forschung Thürin­gen (STIFT) and three new pri­vate investors invested in SmartDyeLivery´s devel­op­ment of inno­v­a­tive nan­oth­er­a­pies. The new group of pri­vate investors was formed with the sup­port of the busi­ness angel and finance & M&A con­sul­tant Louis Moser from Munich/Grünwald, who again invested in the com­pany.

Smart­Dye­Liv­ery devel­ops a plat­form tech­nol­ogy for the tar­geted trans­port of active phar­ma­ceu­ti­cal ingre­di­ents. Based on func­tion­al­ized nan­otrans­porters, active sub­stances are specif­i­cally deliv­ered to affected organs of the body. «Our goal is to develop nanopar­ti­cles with high cell speci­ficity in which drugs can be encap­su­lated in order to treat dis­eases in a more pre­cise way, min­i­mize or even entirely avoid side effects and ulti­mately save human lives,» said Dr. Marc Lehmann, CEO of Smart­Dye­Liv­ery. Espe­cially in the con­text of the company´s first appli­ca­tion of nan­otrans­porters for a spe­cific ther­apy for sep­tic liver fail­ure, the invest­ment enables impor­tant devel­op­ment steps on the path to mar­ket approval.

About Smart­Dye­Liv­ery: Jena-based Smart­Dye­Liv­ery GmbH is devel­op­ing a uni­ver­sal plat­form tech­nol­ogy based on func­tion­al­ized nanopar­ti­cles that can be used to trans­port active ingre­di­ents or other car­gos to the desired site of action. The company´s aim is to pro­vide new ther­a­peu­tic options for dis­eases that have pre­vi­ously been untreat­able or extremely dif­fi­cult to treat. The inno­v­a­tive, patented tech­nol­ogy can also be used for diag­nos­tic or ther­ag­nos­tic appli­ca­tions.

Fur­ther infor­ma­tion can be found at: www.smartdyelivery.de/en/

About bm|t

Erfurt-based bm|t is a sub­sidiary of the Thüringer Auf­baubank and the lead­ing address for equity invest­ments in Thürin­gen, Ger­many. bm|t cur­rently man­ages nine funds with a total vol­ume of around EUR 420 mil­lion, which invest in inno­v­a­tive com­pa­nies across almost all sec­tors and in all phases of com­pany devel­op­ment.

Fur­ther infor­ma­tion about bm|t is avail­able at: www.bm‑t.com

About the STIFT

The STIFT sup­ports, pro­motes and accom­pa­nies inno­v­a­tive tech­nol­ogy-ori­ented and inno­v­a­tive busi­ness start-ups in Thürin­gen, Ger­many within the ThEx project. The STIFT also invests in selected high-tech start-ups as a co-investor. For its invest­ment activ­i­ties, the degree of inno­va­tion of the found­ing idea and the entre­pre­neur­ial poten­tial form the main cri­te­ria.

Fur­ther infor­ma­tion is avail­able at: www.stift-thueringen.de

Con­tact per­sons:

Dr. Marc Lehmann
CEO
Smart­Dye­Liv­ery GmbH
Botzs­traße 5
07743 Jena

 

Ste­fan Jahn
Senior Invest­ment Man­ager
bm‑t beteili­gungs­man­age­ment thürin­gen gmbh
Gork­istraße 9
99084 Erfurt

Back To Top
×Close search
Search